PYC is using its expertise in RNA drug design and proprietary drug delivery technology to bring a powerful new class of precision medicine to patients. With an initial focus on rare eye disease, PYC’s technology has the potential to unlock treatments for multiple types of genetic disease.
- The company has proven the efficacy and safety of its lead drug program in patient-derived models and has launched formal studies in preparation for human clinical trials in 2021.
- PYC is advancing several earlier stage retinal assets and is applying its technology in other tissues including CNS and liver.
- With its research operations based in Australia, PYC recently opened its office in Cambridge, Massachusetts, where the CEO and Chief Medical Officer are now based.
In the short-term, PYC will further de-risk its lead program through pre-clinical toxicity studies, obtain Orphan Drug Designation from the FDA, and file provisional patents for additional drug programs. In the long-term, PYC is building a global RNA therapeutics company with multiple drugs providing treatment to patients with a variety of genetic diseases.
PYC is an emerging company with differentiated technology operating in a field with tremendous growth. The company’s lead asset has been significantly de-risked, and PYC’s broader drug pipeline and technology hold the potential for massive growth.